NeuBase Therapeutics, Inc. – NASDAQ:NBSE

Add to watchlist

Market closed

Open in 3 days

-12.09%

month

-44.41%

quarter

+99.05%

year

Market Cap	1.41M
Enterprise value	N/A

P/E	-0.18
EV/Sales	N/A
EV/EBITDA	0.83
Price/Sales	N/A
Price/Book	N/A
PEG ratio	0.01
EPS	-9.77

Revenue	N/A
EBITDA	-18.46M
Income	-16.83M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

NeuBase Therapeutics, Inc. (NASDAQ:NBSE): Profit margin
Sep 2022	0	-7.54M
Mar 2023	0	-4.02M
Jun 2023	0	-3.44M
Sep 2023	0	-1.82M

NeuBase Therapeutics Financials Estimate

Q Y

NeuBase Therapeutics, Inc. (NASDAQ:NBSE): Analyst Estimates
2027	152.2K	-3.00M	-1974.42%

Analysts Price target
Financials & Ratios estimates

NeuBase Therapeutics, Inc. (NASDAQ:NBSE): Debt to assets
Dec 2022	25583136	7.35M	28.77%
Mar 2023	21458913	7.01M	32.67%
Jun 2023	22333625	11.08M	49.64%
Sep 2023	18621272	9.48M	50.93%

NeuBase Therapeutics, Inc. (NASDAQ:NBSE): Cash Flow
Sep 2022	-6.63M	-28.80K	-27.30K
Mar 2023	-3.44M	-4.94K	-88.42K
Jun 2023	-3.64M	-2	4.54M
Sep 2023	-2.00M	0	-174.5K

NeuBase Therapeutics alternative data

NeuBase Therapeutics
Employees

NeuBase Therapeutics, Inc. (NASDAQ:NBSE): Employee count
Aug 2023	37
Sep 2023	37
Oct 2023	37
Nov 2023	37
Dec 2023	37
Jan 2024	37
Feb 2024	37
Mar 2024	37
Apr 2024	37
May 2024	37
Jun 2024	37
Jul 2024	37

NeuBase Therapeutics
Hedge Funds Holdings Q1 2023

10.71% -20.50%

of NBSE is owned by hedge funds

20 -12

hedge funds hold NBSE stock

3.53M -6.60M

shares is hold by hedge funds

NBSE hedge funds holdings changes

NeuBase Therapeutics
Insider Trading

NeuBase Therapeutics, Inc. (NASDAQ:NBSE): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	61076	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	1 Sep 2023	SYMETRYX CORP 10 percent owner 10 percent owner	Common Stock, Par Value $0.0001 per Share	61,076	$0.98	$59,732
Option	2 Aug 2023	STEPHAN DIETRICH A director, 10 perc..	Common Stock	93,234	$0.02	$2,051
Option	2 Aug 2023	STEPHAN DIETRICH A director, 10 perc..	Stock option (right to buy)	93,234	$0.02	$2,051
Option	13 Feb 2023	STEPHAN DIETRICH A director, 10 perc..	Stock option (right to buy)	655,000	N/A	N/A
Option	13 Feb 2023	STEPHAN DIETRICH A director, 10 perc..	Common Stock	655,000	N/A	N/A
Option	28 Sep 2022	STEPHAN DIETRICH A director, 10 perc..	Stock option (right to buy)	750,000	$0	$750
Option	28 Sep 2022	STEPHAN DIETRICH A director, 10 perc..	Common Stock	750,000	$0	$750
Purchase	30 Mar 2022	MANN WILLIAM ROLAND officer: Chief Operating Officer officer: Chief Operating Officer	Common stock	6,200	$1.92	$11,904
Purchase	18 Mar 2022	BRANNING TODD P. officer: Chief Financial Officer officer: Chief Financial Officer	Common stock	10,000	$1.81	$18,100
Purchase	17 Mar 2022	BRANNING TODD P. officer: Chief Financial Officer officer: Chief Financial Officer	Common stock	10,000	$1.74	$17,400

NBSE insider trading transactions

NeuBase Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q4 2017 15 Dec 2017	Q4 2017 Earnings Call Transcript
Q3 2017 10 Aug 2017	Q3 2017 Earnings Call Transcript
Q2 2017 13 May 2017	Q2 2017 Earnings Call Transcript
Q1 2017 14 Feb 2017	Q1 2017 Earnings Call Transcript

NBSE earnings call transcripts

NeuBase Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Dietrich A. Stephan Ph.D. (1969) Founder, Pres, Chief Executive Officer, Chairman & Interim Chief Financial Officer	56		$713,830
Dr. William Roland Mann MBA, Ph.D. (1960) Chief Operating Officer	65		$470,400

NeuBase Therapeutics
Latest News

Friday, 5 April 2024
16:05	NeuBase Therapeutics Announces Receipt of Notice from Nasdaq	globenewswire.com
Tuesday, 26 March 2024
09:08	Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?	InvestorPlace
Thursday, 14 September 2023
12:00	Cheap Penny Stocks To Buy Now? 3 For Your Watch List	PennyStocks
Thursday, 7 September 2023
12:47	NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake	Zacks Investment Research
Wednesday, 6 September 2023
08:04	Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?	InvestorPlace
Tuesday, 2 May 2023
17:00	NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting	GlobeNewsWire
Friday, 20 January 2023
13:32	What Makes NeuBase (NBSE) a New Strong Buy Stock	Zacks Investment Research
07:32	New Strong Buy Stocks for January 20th	Zacks Investment Research
Tuesday, 27 December 2022
11:13	Best Penny Stocks To Buy? 10 Under $1 To Watch This Week	PennyStocks
Friday, 23 December 2022
12:45	Best Penny Stocks To Buy? 6 Under $1 To Watch Now	PennyStocks
Monday, 17 October 2022
13:33	NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce	Zacks Investment Research
Wednesday, 24 August 2022
13:32	NeuBase (NBSE) Moves to Buy: Rationale Behind the Upgrade	Zacks Investment Research
Monday, 7 March 2022
08:00	NeuBase to Present at Oppenheimer's 32nd Annual Healthcare Conference	GlobeNewsWire
Tuesday, 28 September 2021
16:05	NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference	GlobeNewsWire
Wednesday, 15 September 2021
16:05	NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit	GlobeNewsWire
Wednesday, 1 September 2021
16:05	NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

When is NeuBase Therapeutics's next earnings date?

Unfortunately, NeuBase Therapeutics's (NBSE) next earnings date is currently unknown.
Does NeuBase Therapeutics pay dividends?

No, NeuBase Therapeutics does not pay dividends.
How much money does NeuBase Therapeutics make?

NeuBase Therapeutics has a market capitalization of 1.41M.
What is NeuBase Therapeutics's stock symbol?

NeuBase Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NBSE".
What is NeuBase Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of NeuBase Therapeutics?

Shares of NeuBase Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are NeuBase Therapeutics's key executives?
NeuBase Therapeutics's management team includes the following people:
- Dr. Dietrich A. Stephan Ph.D. Founder, Pres, Chief Executive Officer, Chairman & Interim Chief Financial Officer(age: 56, pay: $713,830)
- Dr. William Roland Mann MBA, Ph.D. Chief Operating Officer(age: 65, pay: $470,400)
Is NeuBase Therapeutics founder-led company?

Yes, NeuBase Therapeutics is a company led by its founder Dr. Dietrich A. Stephan Ph.D..
How many employees does NeuBase Therapeutics have?

As Jul 2024, NeuBase Therapeutics employs 37 workers.
When NeuBase Therapeutics went public?

NeuBase Therapeutics, Inc. is publicly traded company for more then 21 years since IPO on 28 May 2004.
What is NeuBase Therapeutics's official website?

The official website for NeuBase Therapeutics is neubasetherapeutics.com.
Where are NeuBase Therapeutics's headquarters?

NeuBase Therapeutics is headquartered at 350 Technology Drive, Pittsburgh, PA.
How can i contact NeuBase Therapeutics?

NeuBase Therapeutics's mailing address is 350 Technology Drive, Pittsburgh, PA and company can be reached via phone at +64 6 450 1790.

NeuBase Therapeutics, Inc.

neubasetherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

+64 6 450 1790

350 Technology Drive
Pittsburgh, PA 15219

CIK: 0001173281
ISIN: US64132K2015
CUSIP: 64132K102